Advertisement Smiths Medical granted clearance for CADD-Solis system - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Smiths Medical granted clearance for CADD-Solis system

Smiths Medical, part of the global technology business Smiths Group, has received 510(k) clearance from the FDA for its CADD-Solis Ambulatory Infusion System, a next generation ambulatory infusion platform that enhances patient safety and personalized care for pain management patients.

Ambulatory infusion systems, like the CADD-Solis system, administer pain management medications, including narcotics, via a variety of delivery routes including intravenous and epidural.

Jim Stitt, president of Smiths Medical, said: “By involving both clinicians and the human factors engineering team at the University Health Network in Toronto in all phases of the development process, we strove to design a safe, easy-to-use system that brings exceptional value in helping hospitals reduce the risk of programming medication errors while providing better patient care management.”